Nuclear Regulatory Commission.
Notice of availability.Start Further Info
FOR FURTHER INFORMATION CONTACT:
John Nicholson, Commercial and R&D Branch, Division of Nuclear Materials Safety, Region I, 475 Allendale Road, King of Prussia, Pennsylvania, 19406, telephone (610) 337-5236, fax (610) 337-5269; or by email: firstname.lastname@example.org.End Further Info End Preamble Start Supplemental Information
The Nuclear Regulatory Commission (NRC) is issuing a license amendment to Pharmacopeia, Inc. for Materials License No. 29-30152-01, to authorize release of its facility in Monmouth Junction, New Jersey for unrestricted use. NRC has prepared an Environmental Assessment (EA) in support of this action in accordance with the requirements of 10 CFR part 51. Based on the EA, the NRC has concluded that a Finding of No Significant Impact (FONSI) is appropriate. The amendment will be issued following the publication of this Notice.
II. EA Summary
The purpose of the action is to authorize the release of the licensee's Monmouth Junction, New Jersey facility for unrestricted use. Pharmacopeia, Inc. was authorized by NRC from February 1999 to use radioactive materials for research and development purposes at the site. On April 28, 2004, Pharmacopeia, Inc. requested that NRC release the facility for unrestricted use. Pharmacopeia, Inc. has conducted surveys of the facility and provided information to the NRC to demonstrate that the site meets the license termination criteria in Subpart E of 10 CFR part 20 for unrestricted use. Pharmacopeia, Inc. will continue licensed activities at another location, as authorized by the license.
The NRC staff has prepared an EA in support of the license amendment. The facility was remediated and surveyed prior to the licensee requesting the license amendment. The NRC staff has reviewed the information and final status survey submitted by Pharmacopeia, Inc. Based on its review, the staff has determined that there are no additional remediation activities necessary to complete the proposed action. Therefore, the staff considered the impact of the residual radioactivity at the facility and concluded that since the residual radioactivity meets the requirements in Subpart E of 10 CFR Part 20, a Finding of No Significant Impact is appropriate.
III. Finding of No Significant Impact
The staff has prepared the EA (summarized above) in support of the license amendment to release the facility for unrestricted use. The NRC staff has evaluated Pharmacopeia, Inc.”s request and the results of the surveys and has concluded that the completed action complies with the criteria in Subpart E of 10 CFR Part 20. The staff has found that the environmental impacts from the action are bounded by the impacts evaluated by NUREG-1496, Volumes 1-3, “Generic Environmental Impact Statement in Support of Rulemaking on Radiological Criteria for License Termination of NRC-Licensed Facilities' (ML042310492, ML042320379, and ML042330385). On the basis of the EA, the NRC has concluded that the environmental impacts from the action are expected to be insignificant and has determined not to prepare an environmental impact statement for the action.Start Printed Page 3568
IV. Further Information
Documents related to this action, including the application for the license amendment and supporting documentation, are available electronically at the NRC's Electronic Reading Room at http://www.nrc.gov/reading-rm/adams.html. From this site, you can access the NRC's Agencywide Document Access and Management System (ADAMS), which provides text and image files of NRC's public documents. The ADAMS accession numbers for the documents related to this Notice are: The Environmental Assessment (ML043340345), Letter dated April 28, 2004, requesting the amendment (ML041330096), Letter dated September 14, 2004, providing additional information (ML042720160), and Letter from New Jersey Department of Environmental Protection dated November 15, 2004 (ML043290297). Please note that on October 25, 2004, the NRC terminated public access to ADAMS and initiated an additional security review of publicly available documents to ensure that potentially sensitive information is removed from the ADAMS database accessible through the NRC's web site. Interested members of the public may obtain copies of the referenced documents for review and/or copying by contacting the Public document Room pending resumption of public access to ADAMS. The NRC Public documents Room is located at NRC Headquarters in Rockville, MD, and can be contacted at (800) 397-4209 or (301) 415-4737, or by email to email@example.com. The PDR reproduction contractor will copy documents for a fee. The PDR is open from 7:45 a.m. to 4:15 p.m., Monday through Friday, except on Federal holidays.Start Signature
Dated at King of Prussia, Pennsylvania, this 14 day of January, 2005.
For the Nuclear Regulatory Commission.
Chief, Commercial and R&D Branch, Division of Nuclear Materials Safety Region I.
[FR Doc. 05-1282 Filed 1-24-05; 8:45 am]
BILLING CODE 7590-01-P